Global Psoriatic Arthritis Therapeutics Market 2019-2023

#Snapshot img { margin: 10px !important; } A few of the key findings from our psoriatic arthritis therapeutics market forecast report are summarized below See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the report.Get a FREE sample now!Global Psoriatic Arthritis Therapeutics Industry OverviewDifficulty in identifying the pathogenesis of psoriatic arthritis has resulted in the lack of curative therapies for the indication. This has driven market vendors and research organizations to focus on the development of regenerative therapies such as stem cell therapy for curing psoriatic arthritis. One such development is the administration of umbilical cord Wharton’s Jelly stem cells (WJSCs) in psoriatic arthritis patients. Studies conducted by Invitrx Inc. have also shown that the human umbilical cord stem cell therapy can provide complete remission of symptoms such as joint pain and psoriatic plaques and normalize inflammatory markers C-reactive protein and erythrocyte sedimentation rate. These methods of treatment have proven to be highly effective in curing psoriatic arthritis. Although these regenerative therapies are in the early stages of development, further advances in research will boost their demand for the identification of pathogenesis and cause of psoriatic arthritis. Thus, the advent of regenerative therapy has been identified as one of the critical psoriatic arthritis therapeutics market trends. The trend will have a positive influence on the growth of the market over the forecast period.The expiry of patents of most of the drugs in the global PsA therapeutics market has resulted in the development of biosimilars of significant therapeutics. Although biosimilars are reasonably priced, their cost is still higher than small molecule drugs. The high efficacy of biologics in the treatment of psoriatic arthritis therapeutics is also responsible for their increased sales. These factors are restricting the growth of small molecule drugs. Moreover, the patent expansion of the key blockbuster drug, HUMIRA, will help in partially offsetting the value erosion caused by the entry of biosimilars. As a result, the dominance of biologics will grow and drive the psoriatic arthritis therapeutics market growth at a CAGR of almost 9% during the forecast period.Top Psoriatic Arthritis Therapeutics Companies Covered in the Market Research ReportThe global psoriatic arthritis therapeutics market is concentrated. To help clients in improving their market positions, the report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. Moreover, the market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.The report offers a detailed analysis of several leading psoriatic arthritis therapeutics companies, including:AbbVie Inc.Celgene Corp.Johnson & Johnson Services Inc.Novartis AGPfizer Inc.Psoriatic Arthritis Therapeutics Market Segmentation Based on TypeBiologicsSmall moleculesThe biologics segment will account for the highest psoriatic arthritis therapeutics market share. The strong efficacy of approved drugs, availability of patient assistance programs, strong patient pool, and increasing awareness campaigns are a few of the factors fueling the growth of the segment. The report provides an accurate prediction of the contribution of all the segments to the growth of the psoriatic arthritis therapeutics market size.Psoriatic Arthritis Therapeutics Market Segmentation Based on Geographic RegionAsiaEuropeNorth AmericaROWWith a complete study of the growth opportunities for the companies, it has been identified that North America will account for the highest share of the PsA therapeutics market throughout the forecast period. Factors such as strong dominance of biologics, availability of various patient assistance programs, and the presence of advanced healthcare infrastructure are contributing to the growth of the market in the region.Key Highlights of the Global Psoriatic Arthritis Therapeutics Market for the Forecast Years 2019-2023:CAGR of the market during the forecast period 2019-2023Detailed information on factors that will accelerate the growth of the psoriatic arthritis therapeutics market during the next five yearsPrecise estimation of the global psoriatic arthritis therapeutics market size and its contribution to the parent marketAccurate predictions on upcoming trends and changes in consumer behaviorThe growth of the industry across Asia, Europe, North America, and ROWA thorough analysis of the market’s competitive landscape and detailed information on several v

以下为报告中的关键发现摘要：
查看完整的目录和附录清单，以及报告中的精选插图和示例页面。立即免费获取样本！
全球银屑病关节炎治疗市场概述：银屑病关节炎发病机制的识别困难导致了针对该病症缺乏根治性疗法。这促使市场供应商和研究机构专注于再生疗法的开发，例如干细胞疗法以治愈银屑病关节炎。其中一项进展是向银屑病关节炎患者施用脐带Wharton胶干细胞（WJSCs）。Invitrx Inc. 进行的研究也表明，人脐带干细胞疗法可以完全缓解关节痛和银屑病斑块等症状，并使炎症标志物C反应蛋白和红细胞沉降率恢复正常。这些治疗方法已被证明在治愈银屑病关节炎方面高度有效。尽管这些再生疗法仍处于开发初期阶段，但进一步的研究进展将推动其对银屑病关节炎发病机制和病因的识别需求。因此，再生疗法的出现已被视为银屑病关节炎治疗市场的重要趋势之一。该趋势将在预测期内对市场增长产生积极影响。全球银屑病关节炎治疗市场中的大多数药物的专利到期导致重要治疗生物类似物的开发。尽管生物类似物价格合理，但其成本仍高于小分子药物。生物制剂在银屑病关节炎治疗中的高疗效也是其销量增加的原因。这些因素限制了小分子药物的增长。此外，关键重磅炸弹药物HUMIRA的专利扩展将有助于部分抵消生物类似物进入市场造成的价值侵蚀。因此，生物制剂的统治地位将增强，并在预测期内以接近9%的复合年增长率推动银屑病关节炎治疗市场增长。
报告中涵盖了市场调研报告中的一些顶级银屑病关节炎治疗公司，包括：AbbVie Inc.、Celgene Corp.、Johnson & Johnson Services Inc.、Novartis AG、Pfizer Inc.。
银屑病关节炎治疗市场按类型细分：生物制剂、小分子。生物制剂部门将占据银屑病关节炎治疗市场最高的市场份额。已批准药物的强大疗效、患者援助计划的可用性、强大的患者群体以及日益增长的意识运动是推动该部门增长的因素之一。报告提供了对所有细分市场对银屑病关节炎治疗市场规模贡献的准确预测。
银屑病关节炎治疗市场按地理区域细分：亚洲、欧洲、北美、其他地区。通过对公司增长机会的全面研究，已确定北美将在预测期内占据银屑病关节炎治疗市场最高的份额。生物制剂的强大统治地位、各种患者援助计划的可用性以及先进医疗保健基础设施的存在是推动该地区市场增长的因素。
全球银屑病关节炎治疗市场在预测年份2019-2023的关键亮点：市场在预测期内的复合年增长率、在接下来五年内将促进银屑病关节炎治疗市场增长的各项因素、全球银屑病关节炎治疗市场规模及其对母市场的贡献的精确估计、对即将到来的趋势和消费者行为变化的准确预测、亚洲、欧洲、北美和其他地区行业的增长、市场竞争格局的全面分析以及关于多个公司的详细信息。